Activation of the prostaglandin E₂ EP₂ receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices.

ABSTRACT:

Aim

Renal fibrosis plays a pivotal role in the development and progression of chronic kidney disease, which affects 10% of the adult population. Previously, it has been demonstrated that the cyclooxygenase-2 (COX-2)/prostaglandin (PG) system influences the progression of renal injury. Here, we evaluated the impact of butaprost, a selective EP₂ receptor agonist, on renal fibrosis in several models of kidney injury, including human tissue slices.

Methods

We studied the anti-fibrotic efficacy of butaprost using Madin-Darby Canine Kidney (MDCK) cells, mice that underwent unilateral ureteral obstruction and human precision-cut kidney slices. Fibrogenesis was evaluated on a gene and protein level by qPCR and Western blotting.

Results

Butaprost (50 μM) reduced TGF

SUBMITTER: Jensen MS 

PROVIDER: S-EPMC6767420 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature